Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Deloitte
Mallinckrodt
Fuji
US Army
AstraZeneca
Baxter
Harvard Business School
UBS

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ERGOCALCIFEROL

« Back to Dashboard

Clinical Trials for Ergocalciferol

Trial ID Title Status Sponsor Phase Summary
NCT00114556 The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients Completed Novartis Phase 4 Following liver transplantation, rapid bone loss occurs, particularly within the first 6 months post-transplant. This may be associated with fractures, most notable vertebral. The ability to assess osteoporosis therapies in this system may provide useful information for osteoporosis management in general. Hypotheses: 1. That treatment with the bisphosphonate, zoledronate, at the time of liver transplantation and at 1 month post-transplantation will prevent the early transplant-related bone loss (measured by bone densitometry and biochemical bone markers at 3 months) seen in patients who are not treated with a bisphosphonate 2. That continuing treatment with zoledronate at 3 monthly intervals for a total duration of 12 months will result in further improvements in bone density beyond that seen at 3 months 3. That calcium and vitamin D (vit D) supplementation of liver transplant patients does not prevent marked bone loss following transplantation.
NCT00114556 The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients Completed Royal Prince Alfred Hospital, Sydney, Australia Phase 4 Following liver transplantation, rapid bone loss occurs, particularly within the first 6 months post-transplant. This may be associated with fractures, most notable vertebral. The ability to assess osteoporosis therapies in this system may provide useful information for osteoporosis management in general. Hypotheses: 1. That treatment with the bisphosphonate, zoledronate, at the time of liver transplantation and at 1 month post-transplantation will prevent the early transplant-related bone loss (measured by bone densitometry and biochemical bone markers at 3 months) seen in patients who are not treated with a bisphosphonate 2. That continuing treatment with zoledronate at 3 monthly intervals for a total duration of 12 months will result in further improvements in bone density beyond that seen at 3 months 3. That calcium and vitamin D (vit D) supplementation of liver transplant patients does not prevent marked bone loss following transplantation.
NCT00157066 Effects of Vitamin D Supplementation on Antimycobacterial Immunity Completed Department of Clinical Biochemistry, Homerton Hospital, London E9 6SR, UK N/A The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection.
NCT00157066 Effects of Vitamin D Supplementation on Antimycobacterial Immunity Completed Environmental Health Department, London Borough of Newham, London E15 4SF, UK N/A The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection.
NCT00157066 Effects of Vitamin D Supplementation on Antimycobacterial Immunity Completed Imperial College London N/A The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection.
NCT00157066 Effects of Vitamin D Supplementation on Antimycobacterial Immunity Completed Newham Chest Clinic, London E7 8QP, UK N/A The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection.
NCT00157066 Effects of Vitamin D Supplementation on Antimycobacterial Immunity Completed Northwick Park Hospital, Harrow, UK N/A The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ergocalciferol

Condition Name

Condition Name for Ergocalciferol
Intervention Trials
Vitamin D Deficiency 12
Inflammation 3
Nephrolithiasis 2
Chronic Kidney Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ergocalciferol
Intervention Trials
Vitamin D Deficiency 15
Renal Insufficiency, Chronic 7
Kidney Diseases 7
Inflammation 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ergocalciferol

Trials by Country

Trials by Country for Ergocalciferol
Location Trials
United States 23
Saudi Arabia 4
United Kingdom 2
Thailand 2
United Arab Emirates 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ergocalciferol
Location Trials
New York 5
California 3
Massachusetts 3
Texas 1
Alabama 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ergocalciferol

Clinical Trial Phase

Clinical Trial Phase for Ergocalciferol
Clinical Trial Phase Trials
Phase 4 14
Phase 3 4
Phase 2/Phase 3 2
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ergocalciferol
Clinical Trial Phase Trials
Completed 18
Recruiting 6
Not yet recruiting 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ergocalciferol

Sponsor Name

Sponsor Name for Ergocalciferol
Sponsor Trials
King Faisal Specialist Hospital & Research Center 3
American Heart Association 2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ergocalciferol
Sponsor Trials
Other 53
U.S. Fed 5
NIH 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Teva
Farmers Insurance
Harvard Business School
Johnson and Johnson
Fuji
Boehringer Ingelheim
Argus Health
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.